Herpes Zoster Market Overview:
Herpes zoster, also known as shingles, is a viral disease that is caused by the reactivation of varicella-zoster virus. The disease can be triggered by chicken pox. The global herpes zoster market is anticipated to reach USD 224 Million by 2030 at 8.90% CAGR during the forecast period 2022-2030. Market Research Future (MRFR), in their recently published article, revealed that one of the major factors to trigger the growth of this market is the impressive influence of government initiatives and expenditures in the research and development sector.
The herpes zoster market is expected to be led by the US as the country has several patients who are suffering from the disease. In geriatric population, the chance of contracting disease is quite high and the mortality rate in the region is growing with the introduction of advanced medicines. This can be taken as an important thrust-provider. Advanced medicines are also going to have a substantial impact on the global herpes zoster market.
Request For Free Sample Report: https://www.marketresearchfuture.com/sample request/7137
The global herpes zoster market, as per the MRFR study, is segmented into diagnosis, treatment prevention, route of administration, and end-users.
Based on the diagnosis, the herpes zoster market can be segmented into laboratory testing and others. The laboratory testing segment includes real-time Polymerase Chain Reaction (PCR), immunofluorescence microscopy, and serological testing.
Based on the treatment and prevention segment, the herpes zoster market can be segmented into narcotic medications, antiviral medications, antihistamines, anti-inflammatory medications, capsaicin, anticonvulsants, gels, numbing creams, or patches, vaccines, and others.
Based on the route of administration segment, the herpes zoster market comprises oral, topical, and others.
Based on the end-user segment, the herpes zoster market consists hospitals clinics, diagnostic centers, home care settings, research academic institutes, and others. The hospitals clinics segment is gaining substantial head-start as they are the primary caregiver.
The Americas, Europe, Asia Pacific (APAC), and the Middle East Africa (MEA) are four regions that have been included by MRFR in the study of global herpes zoster market.
The market in the Americas is quite big and it is growing with the support from governments of this region. The region also provides highly advanced healthcare facilities and spreads awareness regarding the infection.
The European region ranks second in terms of valuation. Emerging innovative vaccines for disease herpes zoster are expected to boost the regional market. The APAC and the MEA regions are expected to show substantial growth as effects of the disease is rising. The APAC market is going to benefit from the evolving healthcare infrastructures in emerging economies. In the coming years, the MEA market has the potential to emerge as the fastest growing region. However, the African region may hold back the growth as poor countries from the region are lacking proper healthcare infrastructure and expertise.
Companies are intensely competitive when it comes to take charge of the global herpes zoster market. MRFR included several of them in their report on the market to profile them and understand latest trends. These companies are Foamix Pharmaceuticals (Israel), Astellas Pharma Inc. (Japan), GlaxoSmithKline plc (UK), Geneone Life Science (South Korea), NAL Pharma (Hong Kong), Merck Co. Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), TSRL, Inc. (US) and others.
In June 2019, an article published in 2minute medicine revealed that kids who were given varicella vaccine are less likely to show signs of herpes zoster. The research was conducted on people under 18 years of age. The varicella zoster vaccine is a live attenuated vaccine that can be linked with reactivation of the latent herpes zoster.
In a different study, conducted in May 2019, it is revealed that Sky Zoster NBP608 herpes zoster vaccine is at per with Merck’s Zostavax. This could solve South Korea’ problem regarding the launch of Shingrix.
Table Of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.2 Scope Of The Study
2.2.1 Research Objective
Chapter 3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.4 Macroeconomic Indicators
4.5 Pipeline Products
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
For More Details Browse Complete Report @ https://www.marketresearchfuture.com/reports/herpes-zoster-market-7137
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work processes of the industry, MRFR often plans conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
+1 646 845 9312